Valneva SE (INRLF)
OTCMKTS · Delayed Price · Currency is USD
4.600
0.00 (0.00%)
Nov 5, 2025, 4:00 PM EST
Valneva SE Revenue
Valneva SE had revenue of 48.33M EUR in the quarter ending June 30, 2025, with 26.98% growth. This brings the company's revenue in the last twelve months to 196.33M, up 25.47% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
196.33M EUR
Revenue Growth
+25.47%
P/S Ratio
3.26
Revenue / Employee
275.35K EUR
Employees
713
Market Cap
751.67M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Chrome Holding Co. | 174.90M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 2.61M |
Valneva SE News
- 20 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 24 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 4 weeks ago - Valneva SE (VALN) Lowers 2025 Sales Forecast Amid Vaccine Setback - GuruFocus
- 4 weeks ago - Valneva lowers 2025 financial outlook due to loss of Ixchiq vaccine marketing - Seeking Alpha
- 4 weeks ago - Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates - GlobeNewsWire
- 5 weeks ago - Valneva Reports Strong Four-Year Antibody Persistence For Chikungunya Vaccine IXCHIQ - Nasdaq
- 5 weeks ago - Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 5 weeks ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire